In a rising channel. The way to play it is to wait until it hits the lower trendline or if it breaks over the upper trendline.
PolyMedix raises $4M in private stock sale
BUSINESS SUMMARY
PolyMedix, Inc., a development stage biotechnology company, focuses on treating infectious diseases and cardiovascular disorders with synthetic small molecule compounds that mimic the activity of natural protein molecules, compounds (biomimetics). The company?s clinical stage compounds include PMX-30063, a defensin mimetic i.v. antibiotic; and PMX-60056 ? Heptagonist, an unfractionated heparin and low molecular weight heparins reversing agent. Its pre-clinical stage compounds include PMX-30063, a defensin mimetic ophthalmic antibiotic for the treatment of eye infections; PMX-70004 and PMX-50003 that are defensin mimetic polymer biomaterials; PMX-30063, a defensin mimetic oral antibiotic for the treatment of gastrointestinal infections, such as Clostridium difficile; PMX-10098, a defensin mimetic anti-fungal/viral compound; and PMX-20005, an angiogenesis inhibitor for the treatment of cancer. The company was founded in 2002 and is based in Radnor, Pennsylvania.
Full Time Employees: 13
Shares Outstanding5: 53.54M
Float: 48.50M
% Held by Insiders1: 16.28%
Income Statement
Revenue (ttm): 1.73M
Revenue Per Share (ttm): 0.057
Qtrly Revenue Growth (yoy): -89.30%
Gross Profit (ttm): 1.13M
EBITDA (ttm): -12.73M
Net Income Avl to Common (ttm): -12.66M
Diluted EPS (ttm): -0.42
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 3.48M
Total Cash Per Share (mrq): 0.065
Total Debt (mrq): 171.00K
Total Debt/Equity (mrq): 1.541
Current Ratio (mrq): 1.06
Book Value Per Share (mrq): 0.003
Cash Flow Statement
Operating Cash Flow (ttm): -9.27M
Levered Free Cash Flow (ttm): -6.29M
PYMX.OB PolyMedix, Inc. Biotechnology 
Linear Mode
